Staar’s Visian TICL requires FDA panel review
This article was originally published in The Gray Sheet
Executive Summary
PMA supplement for Staar Surgical's Visian TICL toric implantable Collamer lens for treating myopia and astigmatism will require review by the agency's Ophthalmic Devices Panel, contrary to the firm's expectations. As a result, FDA approval will now be "unlikely in 2007, as previously anticipated," Staar says Feb. 6. The panel is needed since Visian TICL is "the first toric phakic implantable lens to be reviewed," according to the company. The supplement, submitted last April, references a December 2005 PMA approval for Staar's Visian ICL for myopia. FDA had asked Staar to amend the Visian TICL supplement last November (1"The Gray Sheet" Dec. 4, 2006, In Brief)...
You may also be interested in...
Staar Surgical warning
Staar hits another snag in its pursuit of approval for its toric implantable lens for astigmatism with the June 27 announcement of an FDA warning letter. The letter, disclosed in a filing with the U.S. Securities and Exchange Commission, resulted from a bioresearch monitoring inspection conducted from Feb. 15 through March 14 and what the agency characterized as inadequate responses to the inspector's written observations. FDA found fault with the firm's oversight of a clinical trial for the investigational Visian TICL phakic collamer lens, citing Staar for failing to ensure that certain clinical sites were covered by an investigational device exemption, among other concerns. The agency already pushed back the firm's expected product approval date last November when it asked for an amendment to Staar's April 2006 PMA supplement application, and again in February when it informed Staar that the product would require advisory panel review (1"The Gray Sheet" Feb. 12, 2007, In Brief)...
FDA delays Staar toric submission
Agency asks Staar Surgical to amend its PMA supplement application for the Visian TICL (toric implantable Collamer lens), a refractive phakic implant placed in the posterior chamber of the eye to treat nearsightedness and astigmatism, firm says Nov. 27. In a Nov. 20 letter, FDA requests more information and analysis of clinical data, which Staar says could extend the review period by up to six months. The original application, which included clinical data from a trial of 125 primary eyes with one-year follow up was submitted April 28 as a supplement to Myopic Visian ICL, approved in December 2005 for correction of myopia...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.